Ipca establishes foothold in US market with CMO purchase

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Ruskpp)
(Image: Getty/Ruskpp)

Related tags Active ingredient

Ipca Laboratories, a fully-integrated Indian pharmaceutical company, has purchased an NC-based CMO in a $9.65m deal that will enable it to manufacture small volume APIs for the US market.

In a filing​ with the Bombay Stock Exchange (BSE​) today, the company announced the purchase of Psgah Labs Inc. by two of its subsidiaries: Ipca Pharmaceutical Inc, USA and Onyx Scientific Ltd.

Pisgah is a US-based contract manufacturing organization (CMO) and active pharmaceutical ingredients (APls) and intermediate developer.

The object of the acquisition is “to establish Company's foothold in the US market in the field of contract research / small volume APls and intermediates manufacturing​,” per Ipca's filing.

For the financial year ending April 2017, Pisgah had a total income of $2.89m and an EBITDA of $1.14m.

According to the company, Onyx and Pisgah's services “dovetail effectively​” with Ipca’s capabilities in supporting Phase II to commercial scale programs.

Ipca purchased Onyx in 2011 – a move which marked the company’s first foray outside of India.

Moving forward, Pisgah will continue to operate out of its North Carolina manufacturing facility under its same name.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers